Therapeutic relevance of pharmacogenetic factors in cardiovascular medicine

被引:22
作者
Nakagawa, K [1 ]
Ishizaki, T [1 ]
机构
[1] Kumamoto Univ, Grad Sch Clin Pharm, Dept Pharmacol & Therapeut, Kumamoto 8620973, Japan
关键词
pharmacogenetics; polymorphism; cytochromes P-450 (CYPs); cardiovascular drugs; cardiovascular diseases; pharmacodynamics;
D O I
10.1016/S0163-7258(99)00066-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The variability in the individual response to drugs may be due either to interindividual variations in the pharmacokinetics of the drugs or to the heterogeneity of the mechanism(s) underlying the diseases, or both. In both cases, genetic heterogeneity is involved in the metabolism of cardiovascular drugs and pathogenesis of inherited cardiovascular disorders. Molecular genetic technologies can now provide sensitive and efficient genetic testing, not only to identify polymorphic drug metabolism genes, but also to identify disease-associated genes for diagnosis and risk stratification of many hereditary cardiovascular diseases. In this review, we discuss the polymorphic metabolism of cardiovascular drugs and the molecular genetics of cardiovascular diseases in relation to the genes determining the responsiveness to a given drug. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1 / 28
页数:28
相关论文
共 360 条
[111]  
HADIDI AHFA, 1988, CANCER RES, V48, P5167
[112]   POTENT INHIBITION OF CYTOCHROME-P450IID6 (DEBRISOQUIN 4-HYDROXYLASE) BY FLECAINIDE INVITRO AND INVIVO [J].
HAEFELI, WE ;
BARGETZI, MJ ;
FOLLATH, F ;
MEYER, UA .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 15 (05) :776-779
[113]   Developmental expression of cytochrome P450 enzymes in human liver [J].
Hakkola, J ;
Tanaka, E ;
Pelkonen, O .
PHARMACOLOGY & TOXICOLOGY, 1998, 82 (05) :209-217
[114]   EFFECT OF THE ACETYLATOR PHENOTYPE ON AMRINONE PHARMACOKINETICS [J].
HAMILTON, RA ;
KOWALSKY, SF ;
WRIGHT, EM ;
CERNAK, P ;
BENZIGER, DP ;
STROSHANE, RM ;
EDELSON, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (06) :615-619
[115]   beta-Blocker use in systolic heart failure and dilated cardiomyopathy [J].
Hash, TW ;
Prisant, LM .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (01) :7-19
[116]   GENETIC POLYMORPHISMS IN THE 5'-FLANKING REGION CHANGE TRANSCRIPTIONAL REGULATION OF THE HUMAN CYTOCHROME P450IIE1 GENE [J].
HAYASHI, S ;
WATANABE, J ;
KAWAJIRI, K .
JOURNAL OF BIOCHEMISTRY, 1991, 110 (04) :559-565
[117]   HIGH SUSCEPTIBILITY TO LUNG-CANCER ANALYZED IN TERMS OF COMBINED GENOTYPES OF P450IA1 AND MU-CLASS GLUTATHIONE-S-TRANSFERASE GENES [J].
HAYASHI, S ;
WATANABE, J ;
KAWAJIRI, K .
JAPANESE JOURNAL OF CANCER RESEARCH, 1992, 83 (08) :866-870
[118]   Interaction between dose and susceptibility to environmental cancer: A short review [J].
Hietanen, E ;
HusgafvelPursiainen, K ;
Vainio, H .
ENVIRONMENTAL HEALTH PERSPECTIVES, 1997, 105 :749-754
[119]  
Hingorani AD, 1995, J HYPERTENS, V13, P1602
[120]   Pharmacogenomics: Will the regulators approve? [J].
Hodgson, J ;
Marshall, A .
NATURE BIOTECHNOLOGY, 1998, 16 (03) :243-+